

27 March 2024

Amendment to ASX announcement dated 27 March 2024 “Osteopore secures Singapore and Vietnam market approvals”

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX:OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – would like to provide an amended version of the ASX announcement released on 27 March 2024.

The amendments to the announcement include:

- The date when the regulatory approvals were received ;
- The estimated financial impact of the regulatory approvals for the Company; and
- Confirmation on how the High Tibial Osteotomy (HTO) market projected growth and market size was calculated.

ENDS

This announcement dated 27 March 2024 has been authorised for release to the ASX by the Company Secretary of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim

CEO & CTO

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

E: istewart@canningspurple.com.au

27 March 2024

Osteopore secures Singapore and Vietnam market approvals

Highlights

- Osteopore secures Singaporean and Vietnamese market approvals to supply its groundbreaking orthopaedic products
- Regulatory clearance includes a suite of off-the-shelf products for High Tibial Osteotomy (HTO), bone grafting, and customisable implants for complex bone loss
- Validates Osteopore's orthopaedic products in the Singaporean and Vietnamese markets, strengthening its positioning in the high-growth global orthopaedic market
- In 2020-21, HTO procedures doubled in Singapore, particularly amongst 40-60-year-olds
- The HTO market is expected to grow at a CAGR of 9.2%, while the general bone grafting market is projected to expand at a CAGR of 2.3%

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX:OSX; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is excited to announce it has secured market approval for its groundbreaking orthopaedic products in Singapore and Vietnam.

On 26 March 2024, Osteopore obtained regulatory clearance from Singapore's Health Sciences Authority (HSA) and Vietnam's Department of Medical Equipment and Construction (DMEC), for aXOpore®, which includes a suite of off-the-shelf and customisable orthopaedic products.

HSA and DMEC clearance positions Osteopore for high-value complex bone reconstruction procedures as well as general bone grafting procedures.

Osteopore's High Tibial Osteotomy (HTO) product is the centrepiece of the Company's orthopaedic expansion into Singapore and Vietnam with the Company paving the way for the product via clinical presentations at opportunities including the Singapore Orthopaedic Association's 45th Annual Scientific Meeting.

According to Singapore General Hospital (SGH), HTO or knee preservation surgeries have doubled in the space of a year – from 50 cases in 2020 to approximately 100 cases in 2021.

More than 10% of adults in Singapore are impacted by knee osteoarthritis, a degenerative joint condition. The prevalence of this condition sees a significant increase amongst 40-to-60-year-olds.

Knee preservation surgeries have the highest potential for this demographic, as they seek to relieve symptoms and delay the need for more invasive surgeries like Total Knee Replacement (TKR)¹.

Vietnam's orthopaedic market is forecasted to experience robust growth at a 7.68% CAGR between 2024 and 2028². This projected expansion is driven by the country's significantly aging population and the increasing prevalence of orthopaedic conditions, which will heighten demand for related products and services.

HTO market projected to grow at a CAGR of 9.2%

According to Osteopore-commissioned market research performed by CETAS Healthcare³, who calculated the HTO market projected growth and market size. The high growth HTO market is projected to grow at a CAGR of 9.2%, with procedures expected to reach 35,000 in the Asia Pacific region (APAC) per annum by 2025⁴. Moreover, it's anticipated that the bone grafting market will increase at a CAGR of 2.3%, while procedures are expected to arrive at 250,000 in APAC per annum by 2025².

HTO, bone grafting and other procedures presents Osteopore with a projected market opportunity of approximately 400,000 procedures in APAC annually by 2025², subject to product availability.

¹ <https://www.sgh.com.sg/news/patient-care/knee-preservation-surgeries-at-sgh-doubles-despite-pandemic>

² <https://www.statista.com/outlook/hmo/medical-technology/medical-devices/orthopedic-devices/vietnam>

³ <https://www.cetas-healthcare.com/>

⁴ Commissioned research (data on file), 2020.

The Company will seek to launch its groundbreaking orthopaedic products in Singapore and Vietnam, which represent two of Osteopore's three highest performing countries over the past 4 years⁵.

Focusing on Singapore and Vietnam enables the Company to leverage its existing sales and distribution channels to accelerate market access, while managing the costs associated with market expansion.

The Company no longer has the ability to sell its aXOpore® products in Singapore under a special access framework, which it has done for the past nine months. As such, the financial impact of the Singapore regulatory approval is estimated to be around 30-50% of the Company's revenues from the Singapore region in the past nine months of up to SGD90k. The Company has no past sales history in Vietnam and the financial impact is unknown.

Commenting on the regulatory clearances and the Company's orthopaedic market expansion into Singapore and Vietnam, Osteopore CEO, Dr Lim Yujing, said:

"We are delighted to share another positive step in the ongoing transformation of the Company.

"The orthopaedic market is a high-value and high-volume segment with the HTO market expected to grow at a CAGR of 9.2%.

"These approvals enable Osteopore to supply off-the-shelf and customisable implants, positioning us to capture the potential of these high growth market segments." said Dr Lim.

ENDS

This announcement dated 27 March 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim

CEO & CTO

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

E: istewart@canningspurple.com.au

⁵ ASX announcement dated 31 March 2023 "Annual Report to Shareholders"

About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Some of the statements appearing in this announcement may be in the nature of forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things. Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by a number of factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control.

The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.



For personal use only